

**Full title:** Surveillance of SARS-CoV-2 lineage B.1.1.7 in Slovakia using a novel, multiplexed RT-qPCR assay

**Short title:** Surveillance of lineage B.1.1.7 in Slovakia

**Authors:** Viera Kováčová (<https://orcid.org/0000-0003-4581-4254>)<sup>1,2†</sup>, Kristína Boršová<sup>3,4†</sup>, Evan D Paul (<https://orcid.org/0000-0002-7011-8050>)<sup>1,2†</sup>, Monika Radvánszka<sup>1,2</sup>, Roman Hajdu<sup>1,2,21</sup>, Viktória Čabanová (<https://orcid.org/0000-0001-8725-9362>)<sup>3</sup>, Monika Sláviková<sup>3</sup>, Martina Ličková (<https://orcid.org/0000-0001-5357-6618>)<sup>3</sup>, Ľubomíra Lukáčiková<sup>3</sup>, Andrej Belák (<https://orcid.org/0000-0001-6634-0137>)<sup>5,6</sup>, Lucia Roussier<sup>6</sup>, Michaela Kostičová<sup>6,7</sup>, Anna Líšková<sup>8</sup>, Lucia Maďarová<sup>9</sup>, Mária Štefkovičová<sup>10,11</sup>, Lenka Reizigová<sup>10,12</sup>, Elena Nováková<sup>13</sup>, Peter Sabaka (<https://orcid.org/0000-0001-9337-8843>)<sup>14</sup>, Alena Koščálová<sup>14,15</sup>, Broňa Brejová (<https://orcid.org/0000-0002-9483-1766>)<sup>16</sup>, Edita Staroňová<sup>17</sup>, Matej Mišík<sup>18</sup>, Tomáš Vinař (<https://orcid.org/0000-0003-3898-3447>)<sup>19</sup>, Jozef Nosek (<https://orcid.org/0000-0002-1020-5451>)<sup>20</sup>, Pavol Čekan<sup>1,2,\*</sup>, Boris Klempa (<https://orcid.org/0000-0002-6931-1224>)<sup>3,\*</sup>

## Affiliations

1. MultiplexDX, Inc., Comenius University Science Park, Bratislava, Slovakia
2. MultiplexDX, Inc., One Research Court, Rockville, MD, USA
3. Biomedical Research Center, Institute of Virology, Slovak Academy of Sciences, Bratislava, Slovakia

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

4. Department of Microbiology and Virology, Faculty of Natural Sciences, Comenius University in Bratislava, Bratislava, Slovakia
5. Institute of Ethnology and Social Anthropology, Slovak Academy of Sciences, Bratislava, Slovakia
6. Intervention team, Ministry of Health, Slovakia
7. Institute of Social Medicine and Medical Ethics, Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovakia
8. Nitra Faculty Hospital, Department of Clinical Microbiology, Nitra, Slovakia
9. Regional Authority of Public Health, Banská Bystrica, Slovakia
10. Regional Authority of Public Health, Trenčín, Slovakia
11. Faculty of Healthcare, Alexander Dubček University of Trenčín, Slovakia
12. Department of Laboratory Medicine, Faculty of Healthcare and Social Work, Trnava University, Trnava, Slovakia
13. Department of Microbiology and Immunology, Comenius University in Bratislava, Jessenius Faculty of Medicine, Martin, Slovakia
14. Department of Infectology and Geographical Medicine, Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovakia
15. Department of Infectious Diseases, Slovak Medical University, Bratislava, Slovakia.
16. Department of Computer Science, Faculty of Mathematics, Physics and Informatics, Comenius University in Bratislava, Bratislava, Slovakia
17. National Influenza Centre, National Public Health Authority of Slovak Republic in Bratislava, Bratislava, Slovakia
18. Institute for Healthcare Analyses, Ministry of Health, Slovakia

19. Department of Applied Informatics, Faculty of Mathematics, Physics and Informatics,  
Comenius University in Bratislava, Bratislava, Slovakia

20. Department of Biochemistry, Faculty of Natural Sciences, Comenius University in  
Bratislava, Bratislava, Slovakia

21. School of Life Sciences, College of Medical, Veterinary and Life Sciences, University of  
Glasgow, Glasgow, UK

† These authors contributed equally

\* **Corresponding author:** Boris Klempa

**Corresponding author email:** boris.klempa@savba.sk

\* **Corresponding author:** Pavol Čekan

**Corresponding author email:** pavol@multiplexdx.com

## **Abstract**

### **Background**

The emergence of a novel SARS-CoV-2 variant of concern called B.1.1.7 lineage sparked global alarm due to evidence of increased transmissibility, mortality, and uncertainty about vaccine efficacy, thus accelerating efforts to detect and track the variant. Current approaches to detect lineage B.1.1.7 include sequencing and RT-qPCR tests containing a target assay that fails or results in reduced sensitivity towards the B.1.1.7 variant.

### **Aim**

Since many countries lack robust genomic surveillance programs and failed assays detect multiple unrelated variants containing similar mutations as B.1.1.7, we sought to develop an RT-qPCR test that can accurately and rapidly differentiate the B.1.1.7 variant from other SARS-CoV-2 variants.

### **Methods**

We used bioinformatics, allele-specific PCR, and judicious placement of LNA-modified nucleotides to develop a test that differentiates B.1.1.7 from other SARS-CoV-2 variants. We validated the test on 106 clinical samples with lineage status confirmed by sequencing and conducted a surveillance study of B.1.1.7 lineage prevalence in Slovakia.

### **Results**

Our multiplexed RT-qPCR test showed 97% clinical sensitivity at detecting lineage B.1.1.7. The assay was used in a country-wide surveillance of B.1.1.7 lineage spread in Slovakia. Retesting nearly 7,000 SARS-CoV-2 positive samples obtained during three campaigns performed within a one month period, revealed pervasive spread of B.1.1.7 with an average prevalence of 82%.

### **Conclusion**

Labs can easily implement this test to rapidly scale B.1.1.7 surveillance efforts and it is particularly useful in countries with high prevalence of variants possessing only the  $\Delta$ H69/ $\Delta$ V70 deletion because current strategies using target failure assays incorrectly identify these as putative B.1.1.7 variants.

**Key words:** B.1.1.7 lineage; 20I/501Y.V1; Variant of Concern (VOC) 202012/01; SARS-CoV-2; COVID-19; RT-qPCR; spike gene; coronavirus

## Introduction

In Dec 2020, Rambaut et al. [1] reported the genomic characterization of a distinct phylogenetic cluster named lineage B.1.1.7 (also referred to as 20I/501Y.V1 by Nextstrain (<https://nextstrain.org/sars-cov-2/>) or Variant of Concern (VOC) 202012/01), briskly spreading over the past four weeks in the United Kingdom. The new lineage has 23 mutations: 13 non-synonymous mutations, 4 deletions, and 6 synonymous mutations. The spike protein contains ten mutations at the amino-acid level ( $\Delta$ H69/ $\Delta$ V70 and  $\Delta$ Y144 deletions, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H) that could potentially change binding affinity of the virus [2–4] and consequently virus-host interaction. Indeed, emerging evidence suggests lineage B.1.1.7 has enhanced transmissibility [3, 5–8], results in higher viral loads [9, 10], and causes increased mortality [11]. These data highlight the need for tools to facilitate enhanced surveillance of lineage B.1.1.7 as well as other variants that may harbour spike gene mutations that alter viral dynamics.

The dominant approach used to putatively detect lineage B.1.1.7 involves conducting multigene RT-qPCR tests that result in positive detection of SARS-CoV-2 in one or more gene sets together with a so-called S gene target failure (SGTF), which is used as a proxy for the B.1.1.7 variant. This approach permits widespread, rapid screening, but is limited by the fact that other variants, in addition to lineage B.1.1.7, produce SGTFs. Thus, the SGTF screening method depends on the presence of other variants in a region and how they vary over time. Whole genome sequencing is the gold-standard for detection of the B.1.1.7 variant. This provides direct confirmation of the variant and identification of emerging variants; however, it is expensive, time consuming, low throughput, and many countries lack a robust genomic surveillance program, making this approach unwieldy to adopt for tracking and mitigating the spread of the B.1.1.7 variant.

Here, we report the development of a novel, multiplexed RT-qPCR test for differentiating lineage B.1.1.7 from all other SARS-CoV-2 lineages. We validated the test using

a selected set of 106 clinical samples collected during routine testing with the lineage status verified by sequencing. Unlike other tests that rely on indirect detection via SGTF, this test contains primers that target the  $\Delta$ H69/ $\Delta$ V70 and  $\Delta$ Y144 deletions in the spike gene that permit the direct detection of lineage B.1.1.7. This assay was used in three rounds of a country-wide screening of the prevalence of B.1.1.7 in Slovakia, which included 6,886 SARS-CoV-2 positive samples, revealing increasing prevalence of lineage B.1.1.7 over time in Slovakia. This RT-qPCR assay provides a useful tool for countries to rapidly identify hot spots of this new B.1.1.7 variant and implement test, trace, and isolate strategies to prevent this variant from becoming widespread. Countries currently experiencing extensive circulation of variants carrying only the  $\Delta$ H69/ $\Delta$ V70 deletion may find this test particularly useful as these would be falsely identified as the B.1.1.7 variant via SGTF tests.

## **Materials and Methods**

### ***Identification of RT-qPCR targets by bioinformatic analysis***

To identify suitable targets for primer/probe design, we downloaded 1,136 sequences from the GISAID repository filtered during a collection time spanning 1 - 21 December 2020. We focused on the spike gene because lineage B.1.1.7 contains a number of spike gene mutations, including two deletions ( $\Delta$ H69/ $\Delta$ V70 and  $\Delta$ Y144) that are ideal for designing a specific assay. We cut the locus encoding the spike protein and used the MAFFT alignment tool (with the parameter - auto)[12] to align all the sequences against the WUHAN reference (NCBI ID: NC\_045512.2). Twelve sequences (1.06 %) contained ambiguous signal in the loci of deletions and were not used in the downstream analysis. We separated sequences into two groups: 1) those with the  $\Delta$ H69/ $\Delta$ V70 and  $\Delta$ Y144 deletions and 2) those without the deletions (**Supplementary Table S1**). Using SeaView [13], we called 95% consensus sequences for

the  $\Delta$ H69/ $\Delta$ V70 and  $\Delta$ Y144 group and the No deletions group that were subsequently used to design primer and probe sets specific to either B.1.1.7 or all other SARS-CoV-2 variants, respectively.

In a separate analysis to determine the prevalence of the  $\Delta$ H69/ $\Delta$ V70 and  $\Delta$ Y144 deletions in lineages other than B.1.1.7, we downloaded 633,137 spike protein sequences with the most recent data description file collected from the beginning of the pandemic through 2 March 2021. Using regular expressions (bash pattern matching command grep with the option -P for Perl-compatible regular expression), we searched for loci with both  $\Delta$ H69/ $\Delta$ V70 and  $\Delta$ Y144 deletions and for loci without these deletions. In the regular expression, we kept fixed a few amino acids downstream and upstream from the deletions to omit any miscalling of the searched pattern. All commands and scripts are available here: <https://github.com/MultiplexDX/B117-RT-qPCR-design/blob/main/B1117.ipynb>.

### ***Primer design and synthesis***

We designed primers and probes using the 95% consensus sequences to target the S gene of the common SARS-CoV-2 (called SARS-CoV-2 S gene assay). To differentiate the B.1.1.7 variant from all other SARS-CoV-2 variants, we also designed primers and probes to target the S gene of SARS-CoV-2 variants containing either the  $\Delta$ H69/ $\Delta$ V70 deletion or the  $\Delta$ Y144 deletion, or both deletions (called B.1.1.7 assay). As an internal control, we synthesized a primer/probe set for human RNase P published by the US CDC [14]. We incorporated locked nucleic acid (LNA)-modified bases into some primers and probes following general guidelines in order to normalize melting temperatures, increase sensitivity, and enhance specificity [15–17]. Following primer/probe design, we conducted *in silico* analyses using the IDT OligoAnalyzer™ tool (<https://www.idtdna.com/pages/tools/oligoanalyzer>) to verify melting temperature ( $T_m$ ), GC content, and potential to form homo-/hetero-dimers as well as the mFold server [18] (<http://www.bioinfo.rpi.edu/applications/mfold/>) to identify problematic secondary structures or



necessary hairpin formation for TaqMan probes. Probes for both SARS-CoV-2 S gene and B.1.1.7 were labelled with a 5'-FAM (6-carboxyfluorescein) reporter dye and 3'-BHQ-1 (black hole quencher 1) dye. In multiplexed reactions, the probe for human RNase P was labelled with a 5'-Cy5 (cyanine 5) reporter dye and 3'-BHQ-3 dye. Primers and probes were synthesized at MultiplexDX, Inc. (Bratislava, Slovakia; <https://www.multiplexdx.com/>). The sequences of primers and probes used in this study are listed in **Supplementary Table S2**. This test is also available as an *in vitro* diagnostic (IVD) CE marked kit called rTest COVID-19 B.1.1.7 qPCR kit (<https://www.multiplexdx.com/products/rtest-covid-19-b-1-1-7-qpcr-kit>, MultiplexDX, Inc.).

### **Positive controls**

For primer/probe set optimization, we used the following positive controls: 1) RNA extracted from a patient confirmed positive for a common variant of SARS-CoV-2 that does not contain any deletions in the spike gene (named wild type template), 2) RNA extracted from a patient confirmed positive for a common variant of SARS-CoV-2 that contains the six base pair deletion (bp: 21765-21770) resulting in the deletion of two amino acids at the 69/70 position of the spike protein (named  $\Delta$ H69/ $\Delta$ V70 template), and 3) RNA extracted from a patient confirmed positive by whole genome sequencing for the SARS-CoV-2 lineage B.1.1.7 (named B.1.1.7 template). The SARS-CoV-2 control samples were confirmed by whole genome sequencing of tiled ~ 2-kbp long amplicons on a MinION device (Oxford Nanopore Technologies, Oxford, UK) essentially as described by Resende *et al.* (2020) [19].

### **RT-qPCR**

We optimized RT-qPCR reactions and conducted clinical validations using both an AriaMx (Agilent, CA, USA) and QuantStudio 5 (ThermoFisher Scientific, MA, USA) real-time PCR system. For all the detected genes, we used the SOLIScript® 1-step CoV Kit (Cat. No.

08-65-00250, SOLIS BioDyne, Tartu, Estonia) according to the manufacturer's recommendations comprised of 4 µl of 5X One-step Probe CoV Mix (ROX), 0.5 µl of 40X One-step SOLIScript® CoV Mix, 2 µl of primers/probe mix, 8.5 µl of PCR water, and 5 µl of sample in a 20 µl total volume. One-step RT-qPCR assays were conducted with the following cycling conditions: 55 °C for 10 min for reverse transcription, 95 °C for 10 min for initial denaturation, and 45 cycles of 95 °C for 15 s and 60 °C for 30 s. Concentrations for primers and probes were as follows: SARS-CoV-2 S gene (forward and reverse primer = 500 nM, probes = 200 nM for each probe (single and dual); B.1.1.7: forward primer = 600 nM, reverse primer = 800 nM, probes = 200 nM for each probe (single and dual); RNase P (forward and reverse primer = 250 nM, probe = 80 nM).

### ***Analytical sensitivity (limit of detection)***

To assess the analytical sensitivity of both our common SARS-CoV-2 S gene (S gene) and B.1.1.7 primer/probe sets, we used RNA isolated from a patient sample infected with the B.1.1.7 variant of SARS-CoV-2 as confirmed by sequencing. This RNA was diluted to 200 copies/µl and then serial dilutions were prepared by diluting the stock with a synthetic matrix "SARS-CoV-2 Negative" (Cat. No. COV000, Exact Diagnostics, TX, USA) containing genomic DNA at a concentration of 75,000 copies/ml, resulting in samples with concentrations of 8 copies/µl (= 40 copies/reaction), 2 copies/µl (= 10 copies/reaction), 0.8 copies/µl (= 4 copies/reaction), 0.4 copies/µl (= 2 copies/reaction) and 0.2 copies/µl (= 1 copy/reaction) that were used in the analytical sensitivity test. The assay was performed in 8 replicates for each prepared dilution.

### ***Clinical performance evaluation***

We evaluated the clinical utility of our SARS-CoV-2 S gene and B.1.1.7 primer/probe sets using a selected set of 106 clinical samples, which were confirmed by an RT-qPCR

reference method used for routine testing by regional public health authorities of the Slovak Republic. Further sequencing revealed 67 of these samples belonging to the B.1.1.7 lineage, 24 samples belonging to the B.1.258 lineage (contains only the  $\Delta$ H69/ $\Delta$ V70 deletion), and 15 samples belonging to other SARS-CoV-2 lineages. The SARS-CoV-2 sequences were determined by sequencing of tiled ~ 2-kbp long amplicons on a MinION device (Oxford Nanopore Technologies, Oxford, UK) as described by Resende et al. (2020) [19].

We conducted a detailed assessment of potential biases and applicability judgements of the clinical validation using the QUADAS-2 tool [20] (<http://www.bristol.ac.uk/population-health-sciences/projects/quadas/quadas-2/>; **Supplementary Table S3**). Inclusion criteria for the selected set of samples consisted of a positive result from a reference standard RT-qPCR test as well as available sequencing information to confirm lineage. No SARS-CoV-2 negative samples were included in the clinical evaluation because in practice this test was to be used only as a tool to identify lineage status in samples previously identified as SARS-CoV-2 positive. The clinical validation was conducted by the Biomedical Research Center, Institute of Virology, Slovak Academy of Sciences (BMC-SAS). BMC-SAS received clinical samples previously identified as SARS-CoV-2 positive by local laboratories, then extracted RNA and performed the index test (rTest COVID-19 qPCR ALLPLEX KIT; MultiplexDX) and the B.1.1.7 test in parallel. All samples were processed and tested in a timely manner to minimize the effects of RNA degradation. For the clinical evaluation, researchers used a prespecified criterion to interpret test results (**Supplementary Table S4**) and were blind to the sequencing outcome.

### ***Surveillance of lineage B.1.1.7 prevalence throughout the Slovak Republic***

This test (rTest COVID-19 B.1.1.7 qPCR kit) was used to assess the prevalence of B.1.1.7 throughout the Slovak Republic over a period of one month. Multiple laboratories of the Public Health Authority of the Slovak Republic retested 6,886 samples that were identified

as SARS-CoV-2 positive by a standard RT-qPCR test. Retesting occurred over a one month period on February 2<sup>nd</sup>, 2021 (1,962 samples), February 17<sup>th</sup>, 2021 (2,382 samples), and March 3<sup>rd</sup>, 2021 (2,542 samples). To ensure sufficient sample size for smaller geographic regions, we grouped districts based on the jurisdictions of the regional public health offices (there are 36 public health offices each covering 1-8 districts) and distributed tests accordingly. Laboratory personnel determined lineage status using the predefined criteria outlined in **Supplementary Table S4**. For comparison with our observed B.1.1.7 prevalences, we also used the prevalences obtained on the first screening round (February 2<sup>nd</sup>, 2021) to estimate historical and future prevalences using a range of two weeks and applying spread factors (3.3 and 5.4) that were derived from estimated reproduction numbers from the UK [5, 8]. Data from the surveillance screening can be found on GitHub: [https://github.com/Institut-Zdravotnych-Analyz/covid19-data/tree/main/PCR\\_Tests](https://github.com/Institut-Zdravotnych-Analyz/covid19-data/tree/main/PCR_Tests).

## Results

### *Identification of RT-qPCR targets by bioinformatic analysis*

Our analysis of 1,136 spike gene sequences (spanning 1 - 21 December 2020) revealed 228 sequences (20%) that contained both the  $\Delta$ H69/ $\Delta$ V70 and  $\Delta$ Y144 deletions (for country of origin, see **Supplementary Table S1**). The shorter deletion ( $\Delta$ Y144) always co-occurred with the longer deletion ( $\Delta$ H69/ $\Delta$ V70), whereas the ( $\Delta$ H69/ $\Delta$ V70) deletion occurs independently in 17 sequences (1.5%). Pearson's correlation coefficient of the deletions is 0.953.

We analysed over 600,000 SARS-CoV-2 genomes to determine the prevalence of both  $\Delta$ H69/ $\Delta$ V70 and  $\Delta$ Y144 deletions in lineage B.1.1.7 and lineages other than B.1.1.7 and found a total of 103,529 sequences that possess both deletions. Based on the metadata file, we

identified SARS-CoV-2 lineages across all called sequences with both deletions. Only 108 sequences (0.10%) out of 103,529 sequences are not labelled as B.1.1.7. In other words, 99.90% of sequences containing both deletions belong to lineage B.1.1.7, highlighting the notion that these two deletions are highly specific for the B.1.1.7 variant and make ideal targets for primer/probe design (**Table 1**).

**Table 1. Summary of GISAID sequences containing both Spike  $\Delta$ H69/ $\Delta$ V70 and  $\Delta$ Y144 deletions**

Clade (Nextstrain)	Total sequences containing both $\Delta$ H69/ $\Delta$ V70 and $\Delta$ Y144	% sequences containing both $\Delta$ H69/ $\Delta$ V70 and $\Delta$ Y144
<b>19A</b>	6	<0.01%
<b>20A</b>	36	0.03%
<b>20A.EU2</b>	22	0.02%
<b>20B</b>	21	0.02%
<b>20C</b>	6	<0.01%
<b>20E.EU1</b>	13	0.01%
<b>20I/501Y.V1 (B.1.1.7)</b>	103,421	99.90%
<b>No ID</b>	4	<0.01%
<b>Total</b>	103,529	100%

***Development of a multiplexed RT-qPCR assay to distinguish lineage B.1.1.7 from all other SARS-CoV-2 variants***

To develop a multiplexed RT-qPCR test to distinguish lineage B.1.1.7, we designed two assays targeting either the wild-type SARS-CoV-2 spike gene or the  $\Delta$ H69/ $\Delta$ V70 and  $\Delta$ Y144 deletions that are highly specific to lineage B.1.1.7 (for primer/probe locations and sequences see **Figure 1** and **Table 2**, respectively).

**Figure 1. Development and optimization of a general SARS-CoV-2 S gene primer/probe set for all SARS-CoV-2 variants.**

Schematic illustrates genomic organization of SARS-CoV-2 with an emphasis on the location of both SARS-CoV-2 S gene and B.1.1.7 primer/probe sets relative to the  $\Delta$ H69/ $\Delta$ V70 and  $\Delta$ Y144 deletions (red lines with ball points) observed in the spike gene of B.1.1.7 variants.

**Table 2. Oligonucleotide primers and probes for common SARS-CoV-2 S gene and B.1.1.7 primer/probe sets**

Oligonucleotide	Sequence	T <sub>m</sub> (°C)	Secondary structure potential (kcal/mol)
SARS-CoV-2 S gene - <b>F1</b>	TCT <b>t</b> T <b>t</b> CCAATGTTACTTGGTTC	54.3	-1.52
SARS-CoV-2 S gene - <b>R1</b>	AGTAGGGACTGGGTCTTCGAATCT	58.9	-0.94
B.1.1.7 - <b>F3</b>	GT <b>t</b> ACT <b>t</b> G <b>G</b> TTCCATGCTATCTC	56.8	1.11
B.1.1.7 - <b>R36</b>	CAACTTT <b>t</b> GTTGTTTTT <b>G</b> tGGTAAGC	58.2	-2.26
SARS-CoV-2 S gene / B.1.1.7 - <b>P3</b>	AGAGGTTTGATAACCCT <b>G</b> tCC <b>t</b> ACCA	61.9	-1.97
SARS-CoV-2 S gene / B.1.1.7- <b>P4</b>	T <b>t</b> TGCTTCCACTGAGAAGT <b>C</b> tAACAT	59.0	-1.48

Nucleotides in lowercase and bold denote LNA-modified bases  
F, forward primer; P, probe; R, reverse primer

We began by designing a general S gene primer/probe assay (SARS-CoV-2 S gene) that could be used for screening purposes and would detect the most common strains of SARS-CoV-2 as well as variants containing the  $\Delta$ H69/ $\Delta$ V70, including lineage B.1.1.7. We assessed the performance of a series of primers flanking the  $\Delta$ H69/ $\Delta$ V70 deletion (**Supplementary Figure S1A, B**; for primer/probes sequences, see **Supplementary Table S2**). After selecting the optimal primer/probe combination, we introduced an additional hydrolysis probe, identically labelled with the same reporter and quencher dyes, that would hybridize in tandem (i.e., on the same strand) with the first hydrolysis probe. Consistent with other reports [21, 22], this dual probe approach enhanced sensitivity and specificity (**Supplementary Figure S1C, D**).

For our assay targeting lineage B.1.1.7, we leveraged the highly specific co-occurrence of the  $\Delta$ H69/ $\Delta$ V70 and  $\Delta$ Y144 deletions in lineage B.1.1.7 (99.90%, **Table 1**). By

designing a series of forward primers to target the  $\Delta$ H69/ $\Delta$ V70 deletion, we differentiated wild type template from  $\Delta$ H69/ $\Delta$ V70 template (**Supplementary Figure S2A**). Since other SARS-CoV-2 variants share the  $\Delta$ H69/ $\Delta$ V70 deletion (e.g., B.1.1.298, B.1.160, B.1.177, B.1.258, B.1.375, B.1.525), we designed a series of reverse primers to target the second, three base pair deletion (bp: 21991-21993;  $\Delta$ Y144) and utilized allele-specific PCR approaches [23–25] and judicious placement of LNA-modified nucleotides to enhance the specificity of the assay (**Supplementary Figure S2B and C**). This approach enabled us to differentiate B.1.1.7 variants that contain both the  $\Delta$ H69/ $\Delta$ V70 and  $\Delta$ Y144 deletions from SARS-CoV-2 variants that contain only the  $\Delta$ H69/ $\Delta$ V70 deletion, provided that a second reaction is ran in parallel using the SARS-CoV-2 S gene set that can be used as a benchmark to assess the relative sensitivity. If the B.1.1.7 primer set amplifies the sample within five Ct cycles of the SARS-CoV-2 S gene primer set, then the sample is B.1.1.7 positive. Alternatively, if the B.1.1.7 primer set amplifies the sample in 8 or more Ct cycles relative to the SARS-CoV-2 S gene primer set, than the sample likely belongs to a variant that contains the  $\Delta$ H69/ $\Delta$ V70 deletion, but not the  $\Delta$ Y144 deletion, and hence is B.1.1.7 negative.

We compared three different versions of B.1.1.7 primer/probe sets using a selected set of 46 samples, some of which were sequenced to confirm lineage status. Given our interpretation criterion (**Supplementary Table S4**), we determined that the V3 primer/probe set performed the best since it correctly identified all B.1.1.7 and  $\Delta$ H69/ $\Delta$ V70 deletion samples, with the exception of one  $\Delta$ H69/ $\Delta$ V70 deletion sample that was interpreted as inconclusive (**Supplementary Figure S3**).

### ***Analytical sensitivity and clinical evaluation of lineage B.1.1.7 S gene primer/probe set***

With our final primer/probe sets for SARS-CoV-2 S gene and B.1.1.7 (**Table 2**), we multiplexed each assay with the US CDC human RNase P primer/probe set (for sequences, see [14]) as an internal control to assess RNA extraction and assay performance. We then determined the analytical sensitivity using serial dilutions of RNA extracted from a B.1.1.7

positive sample. Both assays displayed high sensitivity (**Figure 2A**) with our SARS-CoV-2 S gene and B.1.1.7 assays reliably detecting down to only 2 copies/reaction (0.4 copies/ $\mu$ l) and 10 copies/reaction (2 copies/ $\mu$ l), respectively, placing them among the most sensitive SARS-CoV-2 RT-qPCR assays available.

**Figure 2. Analytical sensitivity and clinical validation of SARS-CoV-2 S gene and B.1.1.7 assays.**

**A)** The limit of detection was determined for both SARS-CoV-2 S gene and B.1.1.7 assays by serial dilutions of isolated viral B.1.1.7 RNA. Data depict the mean and SD of eight replicates per each dilution. The dotted line at Ct 40 serves as a threshold after which amplification is considered invalid. **B)** Overview of  $\Delta$ Ct values (= B.1.1.7 assay Ct – SARS-CoV-2 S gene assay Ct) for each sample in the clinical validation. Symbols represent the various SARS-CoV-2 lineages that were identified by sequencing. Closed symbols represent samples correctly identified by either the SARS-CoV-2 S gene or B.1.1.7 assays, whereas open symbols denote samples that did not meet the criterion established for variant identification. The shaded background shows  $\Delta$ Ct ranges that correspond with the criterion to report a sample as B.1.1.7 positive (pink),  $\Delta$ H69/ $\Delta$ V70 deletion positive (teal), and inconclusive (gray). ND, not detected. **C)** Decision tree demonstrating the proper workflow, interpretation criterion, and actions to implement the SARS-CoV-2 S gene and B.1.1.7 assays a testing regime to identify B.1.1.7 positive samples.

We evaluated the clinical performance of our SARS-CoV-2 S gene and B.1.1.7 assays on 106 clinical samples that underwent sequencing to identify lineage status using interpretation criterion outlined in **Supplementary Table S4**. Our SARS-CoV-2 S gene assay detected all 106 clinical samples regardless of lineage (**Table 3**) confirming its utility as a general screening assay for the most common SARS-CoV-2 variants. Out of 67 clinical samples classified as lineage B.1.1.7 by sequencing, our B.1.1.7 assay positively identified 65 samples, while one sample (Sample 75) was not detected by the B.1.1.7 assay and another sample was deemed inconclusive. The  $\Delta$ Ct of this sample was slightly greater than five cycles (e.g., Sample 40,  $\Delta$ Ct = 5.7) relative to the Ct value for the SARS-CoV-2 S gene assay, which exceeded our cut-off for a positive identification (**Figure 2B**).

**Table 3. Clinical performance of SARS-CoV-2 S gene and B.1.1.7 primer/probes sets.**



Analysed samples	Sequencing	SARS-CoV-2 S gene	B.1.1.7 ( $\Delta$ H69/ $\Delta$ V70 + $\Delta$ Y144)	$\Delta$ H69/ $\Delta$ V70 only	Other lineage of SARS-CoV-2	Inconclusive
B.1.1.7 ( $\Delta$ H69/ $\Delta$ V70 + $\Delta$ Y144)	67	67	65	0	1	1
$\Delta$ H69/ $\Delta$ V70 only	24	24	0	20	3	1
Other lineages of SARS-CoV-2	15	15	0	0	15	0
<b>Total</b>	106	106	65	20	19	2

Notably, our assay was also capable of identifying samples carrying the  $\Delta$ H69/ $\Delta$ V70 deletion such as those belonging to the B.1.258 lineage, provided that the sample contains sufficient viral load as other  $\Delta$ H69/ $\Delta$ V70 variants yield  $\Delta$ Ct values greater than 8 Ct cycles. For the 24 samples that carry only the  $\Delta$ H69/ $\Delta$ V70 deletion and belong to lineage B.1.258, our B.1.1.7 assay correctly identified 20 out of 24 samples. Three samples were not detected by the B.1.1.7 assay possibly due to relatively high Ct values in the SARS-CoV-2 S gene assay for two samples (Sample 33, Ct = 30.1 and Sample 65, Ct = 28.9), making confirmation of the  $\Delta$ H69/ $\Delta$ V70 status impossible with our cut-off criterion. One sample had a  $\Delta$ Ct outside the criterion for  $\Delta$ H69/ $\Delta$ V70 deletion confirmation and was deemed inconclusive. Overall, the clinical evaluation confirmed the diagnostic utility of both our SARS-CoV-2 S gene and B.1.1.7 assays, which showed 100% (106/106) and 97% (65/67) diagnostic sensitivity, respectively. The assay also showed diagnostic utility for identifying variants containing only the  $\Delta$ H69/ $\Delta$ V70 deletion by detecting 83.3% (20/24) of lineage B.1.258 samples. When considering B.1.258 samples containing high viral loads (Ct  $\leq$  28), which is necessary to identify variants with only the  $\Delta$ H69/ $\Delta$ V70 deletion, the diagnostic sensitivity reached 91.7% (22/24). For an overview of the clinical evaluation data, lineage of each sample, and GISAID information, see **Supplementary Table S5**. We have provided a decision tree (**Figure 2C**)

that users may follow to implement this test to directly detect the presence of the B.1.1.7 variant.

### ***Surveillance of lineage B.1.1.7 reveals increasing prevalence throughout the Slovak Republic***

To determine the prevalence of lineage B.1.1.7 and its spread throughout the Slovak Republic, regional public health authorities used this test to screen nearly 7,000 samples previously identified as SARS-CoV-2 positive during three screening rounds over a one month period. The first surveillance screening for lineage B.1.1.7 on February 2<sup>nd</sup>, 2021 revealed a region-specific prevalence of B.1.1.7 ranging from 52% (Žilina) to 85% (Trnava) with an overall B.1.1.7 prevalence of 75% (**Figure 3A-C; Supplementary Table S6**). During the second round of screening held on February 17<sup>th</sup>, 2021, the majority of regions (5 out of 8) showed increased prevalence, although due to reduced prevalence in Banská Bystrica, Košice, and Nitra, the overall prevalence remained at 74%. Closer scrutiny of the data suggests the reduced prevalence in some regions was caused by samples originating from several “non-B.1.1.7 clusters” (e.g., in social care homes), where all positive samples were likely derived from a common infection source. Exclusion of these clusters results in a slight increase in prevalence of 78%. A final screening on March 3<sup>rd</sup>, 2021 showed increased B.1.1.7 prevalence in all regions and an overall prevalence of 85%. Taking into consideration estimates of growth rates (i.e., reproduction number) for lineage B.1.1.7 in the UK [5, 8], we used the prevalences obtained on the first screening round (February 2<sup>nd</sup>, 2021) to estimate historical and future prevalences using a range of two weeks and applying spread factors (3.3 and 5.4) estimated in other countries (**Figure 3D**). Although the expected data did not fit with our observed data, a number of factors likely influence regional spread, including the presence and virulence of competing SARS-CoV-2 lineages and selection biases from cluster outbreaks.

## Figure 5. Tracking the prevalence of lineage B.1.1.7 in Slovakia.

**A)** Maps of the prevalence of lineage B.1.1.7 in the eight regions of Slovakia during the three screening rounds held on February 2<sup>nd</sup>, 2021, February 17<sup>th</sup>, 2021, and March 3<sup>rd</sup>, 2021. Regions in red have prevalence > 80%, regions in yellow have prevalence <60%. **B)** Maps of the prevalence of lineage B.1.1.7 in the 79 districts of Slovakia during the three screening rounds held on February 2<sup>nd</sup>, 2021, February 17<sup>th</sup>, 2021, and March 3<sup>rd</sup>, 2021. Regions in red have prevalence > 80%, regions in yellow have prevalence <60%. **C)** Trends in B.1.1.7 prevalence during the three screening rounds in each of the eight regions of Slovakia. **D)** Observed trends in B.1.1.7 prevalence during the three screening rounds and expected prevalence given various two-week spread factors (shown in parentheses) assuming the prevalence of February 2<sup>nd</sup>, 2021.

## Discussion

The recent emergence of a novel SARS-CoV-2 variant called lineage B.1.1.7 has sparked global consternation as it has now been confirmed in over 70 countries and threatens to exacerbate an already dire pandemic. To mitigate the spread of the B.1.1.7 variant, it is imperative that countries have diagnostic tools that can quickly and accurately detect and track the prevalence of the variant in order to implement the appropriate epidemiological measures. Here we report a novel RT-qPCR test to differentiate the B.1.1.7 variant from other SARS-CoV-2 lineages. The test consists of running two S gene target assays, one specific for B.1.1.7 and the other for all SARS-CoV-2 strains, and performing a simple comparison of relative Ct values that allows the user to differentiate the B.1.1.7 variant from other variants that have the  $\Delta H69/\Delta V70$  deletion. We validated this test on clinical samples that were sequenced to determine the exact SARS-CoV-2 lineage and the results demonstrated a high level of sensitivity in distinguishing the B.1.1.7 variant. Moreover, we retested nearly 7,000 samples previously confirmed as SARS-CoV-2 positive by a reference method in three screening rounds over a one month period, revealing widespread and increasing prevalence of lineage B.1.1.7 throughout the Slovak Republic. This RT-qPCR test allows a positive identification of the B.1.1.7 variant, providing countries with a powerful tool to detect and track lineage B.1.1.7, especially countries that have considerable prevalence of variants carrying only the

$\Delta$ H69/ $\Delta$ V70 deletion [26–29], which are mistakenly identified as B.1.1.7 variants by currently used SGTF assays.

Although there are hundreds of approved RT-qPCR tests for the detection of SARS-CoV-2, few of them are capable of directly differentiating the B.1.1.7 variant from common variants of SARS-CoV-2. Paradoxically, failed RT-qPCR tests have been instrumental in identifying putative B.1.1.7 positive samples and tracking its prevalence [26, 28, 30–33]. These RT-qPCR tests contain multigene assays, with at least one assay targeting the spike gene, and during routine testing a “drop-out” in the spike gene assay may occur (often termed as S gene target failure, or SGTF), while other gene targets yield positive signals. This SGTF can indicate the presence of the B.1.1.7 variant and flag samples for confirmation by sequencing. It is important to note, however, that SGTFs are produced by other variants that contain the  $\Delta$ H69/ $\Delta$ V70 deletion, including the B.1.1, B1.258, B.1.525, and B.1.1.298 (the mink cluster V) lineages, as well [7]. This highlights the importance of follow up sequencing of SGTF samples to determine lineage status.

Indeed, an analysis of SGTFs and corresponding sequencing data by Public Health England revealed that SGTF assays were poor proxies for the presence of B.1.1.7 in early October with only 3% of SGTFs assays positively identifying a B.1.1.7 variant. The SGTF assays only became useful proxies when the variant spread and became more dominant in late November when the assays then detected over 90% of the variant [34]. Others have reached a similar conclusion [5, 27, 28, 31, 32, 35], suggesting that the success of SGTF assays depends on the location, time, and frequency of other variants that contain the  $\Delta$ H69/ $\Delta$ V70 deletion. This is particularly problematic, since the SGTF assays are the least accurate at the time when the B.1.1.7 variant is at low prevalence, precisely the time when an accurate test is needed most in order to establish effective mitigation strategies. Our test outlined here makes significant strides in this effort by accurately differentiating the B.1.1.7 variant with a test that does not rely on a SGTF, thus providing a rapid, accurate test that eliminates the need to conduct expensive and laborious sequencing to confirm lineage status.

Besides the SGTF tests, a number of commercially available SARS-COV-2 variant tests are emerging and have been used as surveillance strategies to monitor the prevalence of variants such as B.1.1.7 [35–40]. These tests are largely based on classical SNP genotyping methods using either probe-based genotyping or melting curve analyses and typically focus on mutations that are shared between many variants (e.g., N501Y, E484K, and  $\Delta$ H69/ $\Delta$ V70 deletion), making it difficult to distinguish between variants unless running multiple SNP assays and then making complex comparisons of melt curves. Similar to SGTF tests, these approaches, while providing a rapid snapshot of the presence of SARS-CoV-2 variants, often require follow up genomic sequencing to identify the particular variant.

Several groups have described publicly available RT-qPCR protocols for detection of lineage B.1.1.7 that can be divided into SNP genotyping assays using either SYBR- [41] or probe-based [42] melting curve analyses, multiplexed probe-based RT-qPCR [43–46], and a combination of target drop-out tests [47]. While these open source RT-qPCR protocols offer cost-effective, rapid strategies to directly detect multiple SARS-CoV-2 variants, some are limited by only assessing a small number of mutations that preclude identification of specific variants and most have yet to be tested in real world surveillance scenarios.

To differentiate B.1.1.7, we took an alternative approach by targeting both the  $\Delta$ H69/ $\Delta$ V70 and  $\Delta$ Y144 deletions using allele-specific PCR methods combined with judicious placement of LNA oligonucleotides. Together, these modifications provided us with a primer/probe set that retained specificity for B.1.1.7 variants and reduced specificity to other variants containing only the  $\Delta$ H69/ $\Delta$ V70 deletion. To highlight the specificity of this assay, our analysis of all GISAID sequences containing both the  $\Delta$ H69/ $\Delta$ V70 and  $\Delta$ Y144 deletions revealed that a staggering 99.90% of all these sequences belong to lineage B.1.1.7, ensuring that users can have high confidence that a positive B.1.1.7 assay result is a true positive. Our test, instead of relying on target failures to identify putative variants, provides a positive signal in the presence of B.1.1.7 and  $\Delta$ H69/ $\Delta$ V70 deletion variants that can easily be differentiated

by comparing their relative Ct values to a common SARS-CoV-2 S gene primer/probe set that serves as a benchmark.

We successfully monitored the dynamics of lineage B.1.1.7 prevalence by retesting nearly 7,000 SARS-CoV-2 positive samples in three successive testing campaigns in Slovakia. This mass surveillance effort provided invaluable information about the spread and prevalence of lineage B.1.1.7 without having to conduct expensive and time-consuming genomic sequencing. Although our observed data did not fit models of previously established replication numbers for lineage B.1.1.7 [5, 8], we attribute this discrepancy to region specific presence of other competing SARS-CoV-2 variants. Indeed, a recently described B.1.258 variant that was extensively circulating throughout the Czech Republic and Slovakia [29] contains mutations in the spike protein (N439K and  $\Delta$ H69/ $\Delta$ V70 deletion) that result in higher viral loads and increased transmissibility [7, 29, 48]. It is plausible that the reproduction number of B.1.1.7 is altered in a time and region-dependent manner that is associated with circulation of B.1.258.

The B.1.1.7 RT-qPCR assay described here was also used to screen for B.1.1.7 prevalence in 122 SARS-CoV-2 positive samples in the city of Trenčín, Slovakia in December 2020. While we observed 81-85% prevalence of B.1.1.7 in the region of Trenčín in February 2021, Brejová and colleagues [29] reported only 4% prevalence of B.1.1.7 and 41% prevalence of variants containing only the  $\Delta$ H69/ $\Delta$ V70 deletion back in December 2020. This highlights two key points: 1) when considering the B.1.1.7 prevalence in Trenčín in December 2020, the extrapolated historical data using estimated reproduction numbers matches our observed prevalence seen in Trenčín region on February 2<sup>nd</sup>, 2021 (**Figure 5C**). 2) SGTF tests utilized early on in a scenario like Trenčín would result in many false positive B.1.1.7 samples. Overall, these data provide real-world evidence of how this B.1.1.7 RT-qPCR assay can be used in mass surveillance screening to capture critical epidemiological information about the dynamics of B.1.1.7. It is also important to note that the outcome of the B.1.1.7 RT-qPCR assay-based screening and the observed trend is greatly in line with the sequence data from

Slovakia available in the GISAID repository (<https://www.gisaid.org/>). From the clinical samples collected in Slovakia in February 2021, 83.8% (n=210) were identified as B.1.1.7 lineage while in the samples from March 2021, 97.1% (n=1336) belonged to the B.1.1.7 lineage.

We have provided interested users with the primer and probe sequences to implement this B.1.1.7 assay in their own laboratories with the hope this can rapidly scale the ability of countries to identify the B.1.1.7 variant and implement epidemiological measures to mitigate its spread. This test can provide labs with a powerful tool to directly confirm the presence of the B.1.1.7 variant in a sample previously determined SARS-CoV-2 positive by an approved screening test, thus avoiding the use of target gene failure assays that can be plagued with low specificity and obviating the need to conduct burdensome and costly genomic sequencing. This is particularly important for countries that are experiencing extensive circulation of variants harbouring only the  $\Delta$ H69/ $\Delta$ V70 deletion as current RT-qPCR assays that rely on SGTFs erroneously classify these samples as presumptive B.1.1.7 variants.

### **Acknowledgements and funding statement**

We gratefully acknowledge the authors from the submitting and originating laboratories that shared genetic sequencing data with the GISAID initiative. We acknowledge the contribution of the oligonucleotide synthesis and production team at MultiplexDX for synthesizing the primers and probes in this study, the laboratory staff of the Slovak regional public health authorities and diagnostic laboratories for screening samples during surveillance of B.1.1.7, and the team at the Institute for Healthcare Analyses for processing the surveillance data. Surveillance of lineage B.1.1.7 using MultiplexDX tests was funded by the Ministry of Health of Slovakia. This project was supported by the European Union's Horizon 2020 research and innovation program [EVA-GLOBAL project, grant agreement number 871029] (BK) and grants

from the Slovak Research and Development Agency: PP-COVID-20-0017 (BK) and PP-COVID-20-0116 (PC, BK).

### **Author contributions**

BK, PC, VK, KB, MM, and EDP conceptualized and planned the study. VK conducted bioinformatic analyses for primer/probe design and inclusivity. PC designed and synthesized primers/probes. MR, RH, KB, VC optimized primer/probe sets on positive controls and clinical samples. AB, LRo, MK, AL, LM, MS, LRe, EN, PS, AK collected and provided clinical samples and associated metadata. KB, VC, BB, JN, TV, performed genomic sequencing and bioinformatics to determine sample lineage status. BK, KB, VC, MS, ML, LL performed clinical validation and analysed clinical data. MM and ES collected and evaluated samples from the B.1.1.7 lineage surveillance and analysed the data. EDP, BK, PC, MM, ES, VK, MR, RH, KB analysed and interpreted the data and wrote the manuscript. All authors provided critical comments and feedback on the manuscript.

### **Conflict of Interest**

VK, EDP, MR, RH, and PC are employees of MultiplexDX, a biotechnology company which has commercialized a kit called rTest COVID-19 B.1.1.7 qPCR kit (<https://www.multiplexdx.com/products/rtest-covid-19-b-1-1-7-qpcr-kit>, MultiplexDX, Inc., Bratislava, Slovakia) that is based on this research. BK is a Head of the Department of Virus Ecology, Institute of Virology, Biomedical Research Center of the Slovak Academy of Sciences (BMC SAS). MM is a Head of the Institute for healthcare analyses at the Slovak Ministry of Health. BMC SAS has entered into collaboration with MultiplexDX, Inc. for development and validation of RT-qPCR tests for routine detection of SARS-CoV-2 and the test for detection of B.1.1.7 variant described in this study. The Ministry of Health procured said tests for the B.1.1.7 lineage surveillance. All other authors declare no competing interests.



## References

1. Rambaut A, Loman N, Pybus O, Barclay W, Barrett J, Carabelli A, et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. *Virological*. 2020. <https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563>. Accessed 13 Jan 2021.
2. GISAID, EpiCoV Data Curation Team. GISAID - UK reports new variant, termed VUI 202012/01. <https://www.gisaid.org/references/gisaid-in-the-news/uk-reports-new-variant-termed-vui-20201201/>. Accessed 18 Jan 2021.
3. Luan B, Wang H, Huynh T. Molecular Mechanism of the N501Y Mutation for Enhanced Binding between SARS-CoV-2's Spike Protein and Human ACE2 Receptor. *bioRxiv*. 2021;:2021.01.04.425316.
4. Starr TN, Greaney AJ, Hilton SK, Ellis D, Crawford KHD, Dingens AS, et al. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. *Cell*. 2020;182:1295-1310.e20.
5. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. *medRxiv*. 2021;:2020.12.30.20249034.
6. Davies NG, Barnard RC, Jarvis CI, Kucharski AJ, Munday J, Pearson CAB, et al. Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England. *medRxiv*. 2020;:2020.12.24.20248822.
7. Kemp SA, Harvey WT, Lytras S, Consortium TC-19 GU (COG-U, Carabelli AM, Robertson DL, et al. Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion H69/V70. *bioRxiv*. 2021;:2020.12.14.422555.
8. Grabowski F, Preibisch G, Giziński S, Kochańczyk M, Lipniacki T. SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations. *Viruses*. 2021;13:392.
9. Kidd M, Richter A, Best A, Mirza J, Percival B, Mayhew M, et al. S-variant SARS-CoV-2 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath RT-QPCR. *medRxiv*. 2020;:2020.12.24.20248834.
10. Golubchik T, Lythgoe KA, Hall M, Ferretti L, Fryer HR, MacIntyre-Cockett G, et al. Early analysis of a potential link between viral load and the N501Y mutation in the SARS-COV-2 spike protein. *medRxiv*. 2021;:2021.01.12.20249080.
11. Horby P, Huntley C, Davies N, Edmunds J, Ferguson N, Medley G, et al. NERVTAG paper on COVID-19 variant of concern B.1.1.7. 2021. <https://www.gov.uk/government/publications/nervtag-paper-on-covid-19-variant-of-concern-b117>. Accessed 28 Jan 2021.
12. Nakamura T, Yamada KD, Tomii K, Katoh K. Parallelization of MAFFT for large-scale multiple sequence alignments. *Bioinformatics*. 2018;34:2490–2.

13. Gouy M, Guindon S, Gascuel O. SeaView version 4: A multiplatform graphical user interface for sequence alignment and phylogenetic tree building. *Mol Biol Evol*. 2010;27:221–4.
14. Centers for Disease Control and Prevention. Research Use Only 2019–Novel Coronavirus (2019-nCoV) Real-time RT-PCR Primers and Probes. 2020. <https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html>. Accessed 4 Feb 2021.
15. McTigue PM, Peterson RJ, Kahn JD. Sequence-Dependent Thermodynamic Parameters for Locked Nucleic Acid (LNA)–DNA Duplex Formation. *Biochemistry*. 2004;43:5388–405.
16. Latorra D, Arar K, Michael Hurley J. Design considerations and effects of LNA in PCR primers. *Molecular and Cellular Probes*. 2003;17:253–9.
17. Levin JD, Fiala D, Samala MF, Kahn JD, Peterson RJ. Position-dependent effects of locked nucleic acid (LNA) on DNA sequencing and PCR primers. *Nucleic Acids Res*. 2006;34:e142–e142.
18. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic Acids Res*. 2003;31:3406–15.
19. Resende PC, Motta FC, Roy S, Appolinario L, Fabri A, Xavier J, et al. SARS-CoV-2 genomes recovered by long amplicon tiling multiplex approach using nanopore sequencing and applicable to other sequencing platforms. *bioRxiv*. 2020;:2020.04.30.069039.
20. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. *Ann Intern Med*. 2011;155:529–36.
21. Yip SP, To SST, Leung PH, Cheung TS, Cheng PK, Lim WW. Use of Dual TaqMan Probes to Increase the Sensitivity of 1-Step Quantitative Reverse Transcription-PCR: Application to the Detection of SARS Coronavirus. *Clin Chem*. 2005;51:1885–8.
22. Nagy A, Vitásková E, Černíková L, Křivda V, Jiřincová H, Sedlák K, et al. Evaluation of TaqMan qPCR System Integrating Two Identically Labelled Hydrolysis Probes in Single Assay. *Scientific Reports*. 2017;7:41392.
23. Gibbs RA, Nguyen PN, Caskey CT. Detection of single DNA base differences by competitive oligonucleotide priming. *Nucleic Acids Res*. 1989;17:2437–48.
24. Tsai MY, Hanson NQ, Copeland KR, Beheshti I, Garg U. Determination of a T/G polymorphism at nucleotide 3206 of the apolipoprotein C III gene by amplification refractory mutation system. *Clin Chem*. 1994;40:2235–9.
25. Lefever S, Pattyn F, Hellemans J, Vandesompele J. Single-nucleotide polymorphisms and other mismatches reduce performance of quantitative PCR assays. *Clin Chem*. 2013;59:1470–80.
26. Bal A, Destras G, Gaymard A, Stefic K, Marlet J, Eymieux S, et al. Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69–V70, France, August to December 2020. *Eurosurveillance*. 2021;26:2100008.
27. Larsen BB, Worobey M. Identification of a novel SARS-CoV-2 Spike 69-70 deletion lineage circulating in the United States - SARS-CoV-2 coronavirus / SARS-CoV-2 Molecular

Evolution. Virological. 2020. <https://virological.org/t/identification-of-a-novel-sars-cov-2-spike-69-70-deletion-lineage-circulating-in-the-united-states/577>. Accessed 29 Jan 2021.

28. Moreno G, Braun K, Larsen BB, Alpert T, Worobey M, Grubaugh N, et al. Detection of non-B.1.1.7 Spike  $\Delta$ 69/70 sequences (B.1.375) in the United States - SARS-CoV-2 coronavirus / nCoV-2019 Genomic Epidemiology. Virological. 2021.

<https://virological.org/t/detection-of-non-b-1-1-7-spike-69-70-sequences-b-1-375-in-the-united-states/587>. Accessed 4 Feb 2021.

29. Brejová B, Hodorová V, Boršová K, Čabanová V, Reizigová L, Paul ED, et al. B.1.258 $\Delta$ , a SARS-CoV-2 variant with  $\Delta$ H69/ $\Delta$ V70 in the Spike protein circulating in the Czech Republic and Slovakia. arXiv:210204689 [q-bio]. 2021. <http://arxiv.org/abs/2102.04689>. Accessed 15 Mar 2021.

30. Washington NL, White S, Barrett KMS, Cirulli ET, Bolze A, Lu JT. S gene dropout patterns in SARS-CoV-2 tests suggest spread of the H69del/V70del mutation in the US. medRxiv. 2020;:2020.12.24.20248814.

31. Alpert T, Lasek-Nesselquist E, Brito AF, Valesano AL, Rothman J, MacKay MJ, et al. Early introductions and community transmission of SARS-CoV-2 variant B.1.1.7 in the United States. medRxiv. 2021;:2021.02.10.21251540.

32. Gaymard A, Bosetti P, Feri A, Destras G, Enouf V, Andronico A, et al. Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France, January to March 2021. Eurosurveillance. 2021;26:2100133.

33. Younes M, Hamze K, Carter DP, Osman KL, Vipond R, Carroll M, et al. B.1.1.7 became the dominant variant in Lebanon. medRxiv. 2021;:2021.03.17.21253782.

34. Variant technical group. Investigation of novel SARS-CoV-2 variant: Variant of Concern 202012/01. Technical briefing 4. Public Health England. 2021;:16.

35. Chen C, Nadeau S, Topolsky I, Manceau M, Huisman JS, Jablonski KP, et al. Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland. medRxiv. 2021;:2021.03.05.21252520.

36. Haim-Boukobza S, Roquebert B, Trombert-Paolantoni S, Lecorche E, Verdurme L, Foulongne V, et al. Rapid SARS-CoV-2 variants spread detected in France using specific RT-PCR testing. medRxiv. 2021;:2021.02.20.21251927.


37. Durner J, Burggraf S, Czibere L, Tehrani A, Watts DC, Becker M. Fast and cost-effective screening for SARS-CoV-2 variants in a routine diagnostic setting. Dent Mater. 2021;37:e95–7.

38. Cabecinhas ARG, Roloff T, Stange M, Bertelli C, Huber M, Ramette A, et al. SARS-CoV-2 N501Y introductions and transmissions in Switzerland from beginning of October 2020 to February 2021 – implementation of Swiss-wide diagnostic screening and whole genome sequencing. medRxiv. 2021;:2021.02.11.21251589.


39. Korukluoglu G, Kolukirik M, Bayrakdar F, Ozgumus GG, Altas AB, Cosgun Y, et al. 40 minutes RT-qPCR Assay for Screening Spike N501Y and HV69-70del Mutations. bioRxiv. 2021;:2021.01.26.428302.

40. Matic N, Lowe CF, Ritchie G, Stefanovic A, Lawson T, Jang W, et al. Rapid detection of SARS-CoV-2 variants of concern identifying a cluster of B.1.1.28/P.1 variant in British Columbia, Canada. medRxiv. 2021;:2021.03.04.21252928.
41. Sater FA, Younes M, Nassar H, Nguewa P, Hamze K. A Rapid and Low-Cost protocol for the detection of B.1.1.7 lineage of SARS-CoV-2 by using SYBR Green-Based RT-qPCR. medRxiv. 2021;:2021.01.27.21250048.
42. Banada P, Green R, Banik S, Chopoorian A, Streck D, Jones R, et al. A Simple RT-PCR Melting temperature Assay to Rapidly Screen for Widely Circulating SARS-CoV-2 Variants. medRxiv. 2021;:2021.03.05.21252709.
43. Nörz D, Grunwald M, Olearo F, Fischer N, Aepfelbacher M, Pfefferle S, et al. Evaluation of a fully automated high-throughput SARS-CoV-2 multiplex qPCR assay with build-in screening functionality for DelHV69/70- and N501Y variants such as B.1.1.7. medRxiv. 2021;:2021.02.12.21251614.
44. Yaniv K, Ozer E, Plotkin N, Bhandarkar NS, Kushmaro A. RT-qPCR assay for detection of British (B.1.1.7) and South Africa (B.1.351) variants of SARS-CoV-2. medRxiv. 2021;:2021.02.25.21252454.
45. Wurtzer S, Waldman P, Levert M, Mouchel JM, Gorgé O, Boni M, et al. Monitoring the propagation of SARS CoV2 variants by tracking identified mutation in wastewater using specific RT-qPCR. medRxiv. 2021;:2021.03.10.21253291.
46. Perchetti GA, Nalla AK, Huang M-L, Jerome KR, Greninger AL. Multiplexing primer/probe sets for detection of SARS-CoV-2 by qRT-PCR. J Clin Virol. 2020;129:104499.
47. Vogels CBF, Alpert T, Breban M, Fauver JR, Grubaugh ND. Multiplexed RT-qPCR to screen for SARS-COV-2 B.1.1.7 variants: Preliminary results - SARS-CoV-2 coronavirus / nCoV-2019 Diagnostics and Vaccines. Virological. 2021. <https://virological.org/t/multiplexed-rt-qpcr-to-screen-for-sars-cov-2-b-1-1-7-variants-preliminary-results/588>. Accessed 29 Jan 2021.
48. Thomson EC, Rosen LE, Shepherd JG, Spreafico R, da Silva Filipe A, Wojcechowskyj JA, et al. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell. 2021. doi:10.1016/j.cell.2021.01.037.


**Figure 1.**



**Figure 2.**




**Figure 3.**



## Supplementary material


### Supplementary Figure S1.



### Supplementary Figure S1. Development and optimization of a general SARS-CoV-2 S gene primer/probe set for all SARS-CoV-2 variants.

**A, B**) Heatmaps illustrate oligonucleotide primer and probe combinations designed to target conserved sequences within the spike gene, including all SARS-CoV-2 variants that were contained in our bioinformatics analysis. Combinations of forward (F1-F4) and reverse primers (R1-R2) and hydrolysis probes (P1-P2) were tested using two separate SARS-CoV-2 variants, a common SARS-CoV-2 variant (Wild type, panel **A**) and a variant containing the  $\Delta$ H69/ $\Delta$ V70 deletion (**B**). Green rectangle boxes indicate best performing primer/probe combinations. **C, D**) Bar graphs compare RT-qPCR performance of a single probe versus an additional identically labelled dual probe using three 10-fold ( $10^1$ ,  $10^2$ ,  $10^3$ ) dilutions of SARS-CoV-2 template ran in triplicates. Evaluation of the performance was done by comparing raw Ct values (**C**) and fluorescence intensity values (**D**). Statistical analysis was performed using paired t-test (\*\* $p \leq 0.001$ , \*\* $p \leq 0.01$ , \* $p \leq 0.05$ ).

## Supplementary Figure S2.




**Figure 2. Development and optimization of a spike gene primer/probe set specific for the B.1.1.7 SARS-CoV-2 variant.**

**A)** Assessment of forward primers (F1-4) targeting the  $\Delta$ H69/ $\Delta$ V70 deletion in B.1.1.7 using the best reverse primer and probe (from **Supplementary Figure S1/ Supplementary Table S2**). Symbols compare Ct values of the  $\Delta$ H69/ $\Delta$ V70 variant and wild type templates. Dotted line indicates samples



that were not detected (ND) within 45 cycles. **B)** Overview of reverse primer designs targeting the  $\Delta Y144$  deletion of the B.1.1.7 variant and their effects on specificity by comparing the relative  $\Delta C_t$  when amplifying either B.1.1.7 or  $\Delta H69/\Delta V70$  variants as template. Darker colours in the heatmap represent a greater  $\Delta C_t$  and consequently better specificity. Green rectangle boxes indicate reverse primers selected for further optimization. LNA-A depicts primers containing an LNA modified adenine base located at either the 3'- or 5'-end of the reverse primer. LNA-T displays the number (1-3) of LNA-modified thymine bases for each reverse primer. Mismatch base represents design modifications to introduce either a guanine (G) or cytosine (C) mismatch base in either the penultimate base (G or C) or the 3<sup>rd</sup> from last base (C-5') relative to the 3'-end of the reverse primer. **C)** Heatmap shows  $\Delta C_t$  value comparison of B.1.1.7 primer/probe set to SARS-CoV-2 S gene primer/probe set using the B.1.1.7 variant as template. Darker colours indicate smaller  $\Delta C_t$  and consequently better specificity.

### Supplementary Figure S3.



### Figure 3. Overview of B.1.1.7 assay performance on clinical samples.

Three different versions (V1, V2, V3) of B.1.1.7 primer/probe sets that varied according to the reverse primer (V1, V2, and V3 use reverse primers R14, R23, and R36, respectively) were directly compared on a selected panel of 46 SARS-CoV-2 positive clinical samples, some of which were confirmed B.1.1.7 and B.1.258 $\Delta$  variants by sequencing.  $\Delta Ct$  values correspond to B.1.1.7 assay Ct – SARS-CoV-2 S gene assay Ct. Coloured boxes within the plot define boundaries for corresponding variant interpretation, red ( $\Delta Ct \pm 5$ ) for B.1.1.7, blue ( $\Delta Ct$  8-20) for  $\Delta H69/\Delta V70$ , grey ( $\Delta Ct$  5-8) for inconclusive samples. N/A represents samples which were detected only in SARS-CoV-2 S gene assay and therefore are interpreted as consensus SARS-CoV-2.

**Supplementary Table S1. Origin and genomic characterization of GISAID sequences used for alignment and primer/probe design.**

<b>Country of origin</b>	<b>Sequences</b>	<b>Omitted</b>	<b>No deletions</b>	<b><math>\Delta</math>H69/<math>\Delta</math>V70 only</b>	<b><math>\Delta</math>Y144 only</b>	<b><math>\Delta</math>H69/<math>\Delta</math>V70 and <math>\Delta</math>Y144</b>
<b>Australia</b>	21	0	20 (95.2 %)	0	0	1 (4.8 %)
<b>Denmark</b>	107	0	99 (92.5 %)	8 (7.5 %)	0	0
<b>UK</b>	965	5	725 (75.5 %)	8 (0.8 %)	0	227 (23.7 %)
<b>New Zealand</b>	13	0	13	0	0	0
<b>Sweden</b>	2	0	2	0	0	0
<b>Thailand</b>	3	0	3	0	0	0
<b>USA</b>	25	0	25	0	0	0
<b>Total</b>	1136	5	887	16	0	228

## Supplementary Table S2. Oligonucleotide primers and probes for common SARS-CoV-2 S gene and B.1.1.7 primer/probe sets.

Oligonucleotide	Sequence	T <sub>m</sub> (°C)	Secondary structure potential (kcal/mol)
<i>Forward primers (F1-F4) targeting all SARS-CoV-2 variants</i>			
SARS-CoV-2 S gene - <b>F1</b>	TCTtTtCCAATGTTACTTGGTTC	54.3	-1.52
SARS-CoV-2 S gene - <b>F2</b>	TCTtTtCCAATGTTACTTGGTtC	55.9	-1.52
SARS-CoV-2 S gene - <b>F3</b>	TtACCTtTCTtTTCCAATGTTAC C	54.5	1.51
SARS-CoV-2 S gene - <b>F4</b>	CTtACCTtTCTtTTCCAATGTtAC	56.4	1.51
<i>Detection probes (P1-P4) targeting all SARS-CoV-2 variants</i>			
SARS-CoV-2 S gene - <b>P1</b>	AGAGGTTTGATAACCCTGTCCTACCA	59.1	-1.97
SARS-CoV-2 S gene - <b>P2</b>	AGAGGTTTGATAACCCTGTCctACCA	60.3	-1.97
SARS-CoV-2 S gene/B.1.1.7 - <b>P3</b>	AGAGGTTTGATAACCCTGtCctACCA	61.9	-1.97
SARS-CoV-2 S gene/B.1.1.7- <b>P4</b>	TtTGCTTCCACTGAGAAGTctAACAT	59.0	-1.48
<i>Reverse primers (R1-R2) targeting all SARS-CoV-2 variants</i>			
SARS-CoV-2 S gene - <b>R1</b>	AGTAGGGACTGGGTCTTCGAATCT	58.9	-0.94
SARS-CoV-2 S gene - <b>R2</b>	GTAGGGACTGGGTCTTCGAATCTA	57.3	-0.94
<i>Forward primers (F1-F4) targeting the 1st deletion (<math>\Delta</math>H69/<math>\Delta</math>V70)</i>			
B.1.1.7 - <b>F1</b>	GTTACTTGGTTCATGCTATCTCTG	55.3	1.11
B.1.1.7 - <b>F2</b>	GTtACTTGGTTCATGCTATCTCT	56.3	1.11
B.1.1.7 - <b>F3</b>	GTtACTtGGTTCATGCTATCTC	56.8	1.11
B.1.1.7 - <b>F4</b>	GTTCCATGCTATCTCTGGGACC	57.1	-0.62
<i>Detection probes (P1-P4) targeting the 1<sup>st</sup> deletion (1)</i>			
B.1.1.7 - <b>P1</b>	ATGCTATCTCTGGGACCAATGGTACT	59.1	-0.96
B.1.1.7 - <b>P2</b>	ATGCTATCTCTGGGACCAATGGtACT	60.9	-0.96
B.1.1.7 - <b>P3</b>	TGCTATCTCTGGGACCAATGGTACT	59.1	-0.96
B.1.1.7 - <b>P4</b>	TGCTATCTCTGGGACCAATGGtACT	61.0	-0.96
<i>Reverse primers (R1-R37) targeting the 2<sup>nd</sup> deletion (<math>\Delta</math>Y144)</i>			
B.1.1.7 - <b>R1</b>	TtTGTTGTTTTGTGGTAAaCACC	55.2	-1.51
B.1.1.7 - <b>R2</b>	TtGTTGTTtTTGTGGTAAaCACC	56.9	-1.51
B.1.1.7 - <b>R3</b>	TGTTGTTtTTGTGGTAAaCACCC	57.1	-1.51
B.1.1.7 - <b>R4</b>	GTTGTTtTTGTGGTAAaCACCC	55.6	-1.51
B.1.1.7 - <b>R5</b>	TtGtTgTTtTTGTGGTAAaCAC	56.6	-1.51
B.1.1.7 - <b>R6</b>	TGtTGtTTTTtGTGGTAAaCAC	56.1	-1.51
B.1.1.7 - <b>R7</b>	CAACtTTTGTGTTTTTGTGGTAAACAC	55.6	-3.34
B.1.1.7 - <b>R8</b>	CAACtTtTGTTGTTTTTGTGGTAAACAC	56.7	-3.34

B.1.1.7 - <b>R9</b>	CA <b>a</b> C <b>t</b> TTTTGTTGTTTTTGTGGTAAACAC	56.6	-3.34
B.1.1.7 - <b>R10</b>	CA <b>a</b> C <b>t</b> T <b>t</b> TGTTGTTTTTGTGGTAAACA	56.0	-2.38
B.1.1.7 - <b>R11</b>	CA <b>a</b> C <b>t</b> T <b>t</b> TGTTGTTTTTGTGGTAAACA	57.0	-2.38
B.1.1.7 - <b>R12</b>	CA <b>a</b> C <b>t</b> T <b>t</b> TGTTGTTTTTGTGGTAAAC	55.8	-2.14
B.1.1.7 - <b>R13</b>	CA <b>a</b> C <b>t</b> T <b>t</b> TGTTGTTTTTGTGGTAAAC	54.7	-2.14
B.1.1.7 - <b>R14</b>	CA <b>a</b> C <b>t</b> TT <b>t</b> TGTTGTTTTTGTGGTAAAC	55.0	-2.14
B.1.1.7 - <b>R15</b>	CA <b>a</b> C <b>t</b> T <b>t</b> TGTTGTTTTTGTGGTAAAC	55.3	-2.14
B.1.1.7 - <b>R16</b>	CA <b>a</b> C <b>t</b> TT <b>t</b> TGTTGTTTTTGTGGTAAAC	54.1	-2.14
B.1.1.7 - <b>R17</b>	CA <b>a</b> C <b>t</b> TT <b>t</b> TGTTGTTTTTGTGGTAAAC	53.8	-2.14
B.1.1.7 - <b>R18</b>	CA <b>a</b> C <b>t</b> TT <b>t</b> TGTTGTTTTTGTGGTAAAC	53.6	-2.14
B.1.1.7 - <b>R19</b>	CA <b>a</b> C <b>t</b> TT <b>t</b> TGTTG <b>t</b> TTTTTGTGGTAAAC	55.4	-2.14
B.1.1.7 - <b>R20</b>	CA <b>a</b> C <b>t</b> T <b>t</b> TGTTG <b>t</b> TTTTTGTGGTAAAC	55.1	-2.14
B.1.1.7 - <b>R21</b>	CA <b>a</b> C <b>t</b> T <b>t</b> TGTTGTTTTTGTGGTAAA	54.4	-2.14
B.1.1.7 - <b>R22</b>	CA <b>a</b> C <b>t</b> TT <b>t</b> TGTTG <b>t</b> TTTTTGTGGTAAA	54.5	-2.14
B.1.1.7 - <b>R23</b>	CA <b>a</b> C <b>t</b> TT <b>t</b> TGTTG <b>t</b> TTTTTGTGGTAAAC	56.3	-2.14
B.1.1.7 - <b>R24</b>	CA <b>a</b> C <b>t</b> T <b>t</b> TGTTG <b>t</b> TTTTTGTGGTAAAC	56.6	-2.14
B.1.1.7 - <b>R25</b>	CA <b>a</b> C <b>t</b> TT <b>t</b> TGTTGTTTTTGTGGTAAACA	56.2	-2.38
B.1.1.7 - <b>R26</b>	CA <b>a</b> C <b>t</b> T <b>t</b> TGTTGTTTTTGTGGTAAACA	56.5	-2.38
B.1.1.7 - <b>R27</b>	CA <b>a</b> C <b>t</b> TT <b>t</b> TGTTG <b>t</b> TTTTTGTGGTAAACA	56.6	-2.38
B.1.1.7 - <b>R28</b>	CA <b>a</b> C <b>t</b> TT <b>t</b> TGTTGTTTTTGTGGTAA <b>CC</b>	56.5	-2.26
B.1.1.7 - <b>R29</b>	CA <b>a</b> C <b>t</b> TT <b>t</b> TGTTGTTTTTGTGGTAA <b>GC</b>	56.7	-2.26
B.1.1.7 - <b>R30</b>	CA <b>a</b> C <b>t</b> T <b>t</b> TGTTGTTTTTGTGGTAA <b>CC</b>	56.9	-2.26
B.1.1.7 - <b>R31</b>	CA <b>a</b> C <b>t</b> T <b>t</b> TGTTGTTTTTGTGGTAA <b>GC</b>	57.1	-2.26
B.1.1.7 - <b>R32</b>	CA <b>a</b> C <b>t</b> T <b>t</b> TGTTGTTTTTGTGGTAA <b>CAC</b>	56.8	-2.26
B.1.1.7 - <b>R33</b>	CA <b>a</b> C <b>t</b> TT <b>t</b> TGTTG <b>t</b> TTTTTGTGGTAA <b>GC</b>	58.0	-2.26
B.1.1.7 - <b>R34</b>	CA <b>a</b> C <b>t</b> TT <b>t</b> TGTTGTT <b>t</b> TTGTGGTAA <b>GC</b>	58.0	-2.26
B.1.1.7 - <b>R35</b>	CA <b>a</b> C <b>t</b> TT <b>t</b> TGTTGTTTT <b>t</b> TTGTGGTAA <b>GC</b>	58.2	-2.26
B.1.1.7 - <b>R36</b>	CA <b>a</b> C <b>t</b> TT <b>t</b> TGTTGTTTT <b>t</b> TTGTGGTAA <b>GC</b>	58.2	-2.26
B.1.1.7 - <b>R37</b>	CA <b>a</b> C <b>t</b> TT <b>t</b> TGTTGTTTT <b>t</b> TTGTGGTAA <b>GC</b>	58.4	-2.26

- Primers/probes highlighted in green comprise the final lineage B.1.1.7 S gene primer/probe set
- Nucleotides in lowercase and bold denote LNA-modified bases
- Nucleotides in red font indicate mismatch bases used for SNP detection
- F, forward primer; P, probe; R, reverse primer

**Supplementary Table S3. Assessment of clinical performance according to QUADUS-2.**

Item	Question	Answer	Domain	Risk of bias
1.	Was a consecutive or random sample of patients enrolled?	Omitted -Not applicable	Patient selection	Low
2.	Was a case-control design avoided?	Yes		
3.	Did the study avoid inappropriate exclusions?	Yes		
4.	<b>Applicability:</b> Are there concerns that the included patients do not match the review question?	Low		
5.	Were the index test results interpreted without knowledge of the results of the reference standard?	Omitted -Not applicable	Index test	Low
6.	If a threshold was used, was it prespecified?	Yes		
7.	<b>Applicability:</b> Are there concerns that the index test, its conduct, or its interpretation differ from the review question?	Low		
8.	Is the reference standard likely to correctly classify the target condition?	Yes	Reference standard	Low
9.	Were the reference standard results interpreted without knowledge of the results of the index test results?	Yes		
10.	<b>Applicability:</b> Are there concerns that the target condition as defined by the reference standard does not match the review question?	No		
11.	Was there an appropriate interval between index test(s) and reference standard?	Yes	Flow and timing	Low
12.	Did all patients receive a reference standard?	Yes		
13.	Did all patients receive the same reference standard?	Unclear		
14.	Were all patients included in the analysis?	Yes		

**Supplementary Table S4. Interpretation of SARS-CoV-2 test results and corresponding actions.**

<b>SARS-CoV-2 S gene</b>	<b><math>\Delta</math>Ct between B.1.1.7 and SARS-CoV-2 S gene<sup>a</sup></b>	<b>Human RNase P</b>	<b>Result interpretation</b>	<b>Report</b>
+	Max 5 Ct	+/ND	SARS-CoV-2 B.1.1.7 detected	SARS-CoV-2 B.1.1.7 positive
+	Min 8 Ct	+/ND	SARS-CoV-2 $\Delta$ H69/ $\Delta$ V70 deletion detected	SARS-CoV-2 B.1.1.7 negative
+	Min 20 Ct	+/ND	Other lineage of SARS-CoV-2 detected	SARS-CoV-2 B.1.1.7 negative
+	ND	+/ND	Consensus or other lineage of SARS-CoV-2 detected	SARS-CoV-2 B.1.1.7 negative
ND	+	+/ND	Inconclusive result	Inconclusive
ND	ND	ND	Invalid result	Invalid

<sup>a</sup>  $\Delta$ Ct = B.1.1.7 assay Ct – SARS-CoV-2 S gene assay Ct  
 ND, not detected

**Supplementary Table S5. Overview of clinical sample RT-qPCR results, lineage, and GISAID information.**

rTEST COVID-19 qPCR B.1.1.7 kit				Sequencing		
Sample ID	B.1.1.7 PCR [Ct]	S gene PCR [Ct]	$\Delta$ Ct	Sequencing outcome (GISAID lineage)	Name in GISAID	Accession ID in GISAID
1	23.8	23.6	0.2	B.1.1.7	UKBA-706	EPI_ISL_875525
2	18.0	18.1	-0.1	B.1.1.7	UKBA-707	EPI_ISL_875526
3	33.9	34.5	-0.5	B.1.1.7	UKBA-801	EPI_ISL_831667
4	36.4	36.0	0.5	B.1.1.7	UKBA-802	EPI_ISL_831668
5	32.3	31.5	0.8	B.1.1.7	UKBA-708	EPI_ISL_875527
6	37.5	35.2	2.3	B.1.1.7	UKBA-803	EPI_ISL_831672
7	23.7	25.0	-1.3	B.1.1.7	UKBA-714	EPI_ISL_875521
8	25.3	24.8	0.5	B.1.1.7	UKBA-713	EPI_ISL_875520
9	No Ct	30.6	-	B.1.160	UKBA-701	EPI_ISL_875530
10	28.8	28.5	0.3	B.1.1.7	UKBA-703	EPI_ISL_875522
11	32.0	26.9	5.0	B.1.1.7	UKBA-705	EPI_ISL_875524
12	25.2	22.9	2.3	B.1.1.7	UKBA-704	EPI_ISL_875523
13	32.2	24.5	7.7	B.1.258	UKBA-702	EPI_ISL_875528
14	No Ct	28.8	-	B.1.1.243	UKBA-715	EPI_ISL_875516
15	No Ct	29.6	-	B.1.177	UKBA-716	EPI_ISL_875533
16	No Ct	24.4	-	B.1.177	UKBA-717	EPI_ISL_875534
17	34.3	29.6	4.7	B.1.1.7	UKBA-718	EPI_ISL_875517
18	30.8	30.2	0.6	B.1.1.7	UKBA-719	EPI_ISL_875518
19	25.2	22.6	2.6	B.1.1.7	UKBA-720	EPI_ISL_875519
20	23.2	13.2	10.1	B.1.258	UKBA-722	EPI_ISL_875529
21	No Ct	12.7	-	B.1.1.170	UKBA-723	EPI_ISL_875532
22	No Ct	25.8	-	B.1.1.170	UKBA-724	EPI_ISL_875538
23	21.1	18.8	2.3	B.1.1.7	UKBA-804	EPI_ISL_831669
24	29.5	26.9	2.6	B.1.1.7	UKBA-805	EPI_ISL_831670
25	22.8	20.8	1.9	B.1.1.7	UKBA-806	EPI_ISL_831673
26	26.2	24.2	2.0	B.1.1.7	UKBA-807	EPI_ISL_831671
27	21.3	18.6	2.6	B.1.1.7	UKBA-808	EPI_ISL_831674
28	26.7	15.2	11.5	B.1.258	UKBA-809	EPI_ISL_831676
29	30.0	27.8	2.3	B.1.1.7	UKBA-814	EPI_ISL_831675
30	23.5	21.8	1.6	B.1.1.7	UKBA-815	EPI_ISL_831663
31	22.9	18.7	4.1	B.1.1.7	UKBA-816	EPI_ISL_831664
32	28.5	24.2	4.3	B.1.1.7	UKBA-817	EPI_ISL_831665
33	No Ct	30.1	-	B.1.258	UKBA-818	EPI_ISL_831666
34	25.4	24.0	1.4	B.1.1.7	UKBA-501	EPI_ISL_779651
35	29.4	29.1	0.3	B.1.1.7	UKBA-502	EPI_ISL_779652
36	30.7	28.9	1.8	B.1.1.7	UKBA-503	EPI_ISL_779653
37	31.5	30.0	1.5	B.1.1.7	UKBA-504	EPI_ISL_779654
38	34.3	29.9	4.4	B.1.1.7	UKBA-505	EPI_ISL_779655



39	31.5	30.8	0.7	B.1.1.7	UKBA-506	EPI_ISL_779656
40	37.9	32.2	5.7	B.1.1.7	UKBA-507	EPI_ISL_779657
41	30.2	29.1	1.1	B.1.1.7	UKBA-508	EPI_ISL_779658
42	37.6	34.4	3.2	B.1.1.7	UKBA-509	EPI_ISL_779659
43	39.7	35.2	4.5	B.1.1.7	UKBA-512	EPI_ISL_779660
44	25.8	14.7	11.1	B.1.258	UKBA-1001	EPI_ISL_903980
45	No Ct	23.1	-	B.1.1.170	UKBA-1002	EPI_ISL_903981
46	24.4	15.2	9.2	B.1.258	UKBA-1004	EPI_ISL_903983
47*	35.8	27.1	8.7	B.1.258	UKBA-1005	EPI_ISL_903984
48*	29.1	18.3	10.8	B.1.258	UKBA-1006	EPI_ISL_903985
49	15.6	16.8	-1.2	B.1.1.7	UKBA-1007	EPI_ISL_903986
50	25.4	16.1	9.3	B.1.258	UKBA-1008	EPI_ISL_903987
51	No Ct	16.5	-	B.1.160	UKBA-1009	EPI_ISL_903988
52	19.9	17.4	2.5	B.1.1.7	UKBA-1010	EPI_ISL_903989
53	27.6	25.5	2.1	B.1.1.7	UKBA-1011	EPI_ISL_903990
54*	37.1	26.0	11.1	B.1.258	UKBA-1012	EPI_ISL_903991
55	No Ct	15.1	-	B.1.177	UKBA-1013	EPI_ISL_903992
56	28.0	19.6	8.4	B.1.258	UKBA-1014	EPI_ISL_903993
57	No Ct	23.4	-	B.1.1.277	UKBA-1015	EPI_ISL_903994
58*	35.5	26.9	8.6	B.1.258	UKBA-1016	EPI_ISL_903995
59	No Ct	16.3	-	B.1.160	UKBA-1017	EPI_ISL_903996
60	33.2	22.9	10.3	B.1.258	UKBA-1018	EPI_ISL_903997
61	26.5	17.5	9.0	B.1.258	UKBA-1020	EPI_ISL_903999
62	19.8	20.7	-0.9	B.1.1.7	UKBA-1021	EPI_ISL_904000
63	No Ct	18.9	-	B.1.221	UKBA-1022	EPI_ISL_904001
64*	35.2	25.3	9.9	B.1.258	UKBA-1023	EPI_ISL_904002
65*	No Ct	28.9	-	B.1.258	UKBA-1024	EPI_ISL_904003
66	21.7	19.4	2.4	B.1.1.7	UKBA-1101	EPI_ISL_959643
67	No Ct	17.1	-	B.1.160	UKBA-1102	EPI_ISL_959642
68	25.8	16.4	9.4	B.1.258	UKBA-1103	EPI_ISL_959648
69	17.7	15.3	2.4	B.1.1.7	UKBA-1104	EPI_ISL_959645
70	No Ct	17.9	-	B.1.1.170	UKBA-1105	EPI_ISL_959647
71	21.7	18.9	2.9	B.1.1.7	UKBA-1106	EPI_ISL_959646
72	26.5	22.6	3.9	B.1.1.7	UKBA-1107	EPI_ISL_959644
73	32.3	20.6	11.6	B.1.258	UKBA-1108	EPI_ISL_959649
74	No Ct	25.0	-	B.1.1.7	UKBA-1109	EPI_ISL_959637
75*	33.8	30.3	3.5	B.1.1.7	UKBA-1110	EPI_ISL_959638
76*	21.0	19.5	1.5	B.1.1.7	UKBA-1111	EPI_ISL_959639
77*	26.3	23.8	2.5	B.1.1.7	UKBA-1112	EPI_ISL_959640
78	No Ct	23.2	-	B.1.1.170	UKBA-1113	EPI_ISL_959641
79	29.9	27.5	2.5	B.1.1.7	UKBA-1114	EPI_ISL_959627
80	32.7	24.2	8.5	B.1.258	UKBA-1115	EPI_ISL_959630
81	31.0	28.8	2.1	B.1.1.7	UKBA-1116	EPI_ISL_959628
82	25.3	23.0	2.3	B.1.1.7	UKBA-1117	EPI_ISL_959626

83	26.9	16.7	10.2	B.1.258	UKBA-1118	EPI_ISL_959631
84	20.9	17.5	3.4	B.1.1.7	UKBA-1119	EPI_ISL_959629
85	23.8	19.0	4.8	B.1.1.7	UKBA-1120	EPI_ISL_959632
86	21.6	19.3	2.2	B.1.1.7	UKBA-1121	EPI_ISL_959633
87	19.0	16.3	2.7	B.1.1.7	UKBA-1122	EPI_ISL_959634
88	19.4	17.2	2.1	B.1.1.7	UKBA-1123	EPI_ISL_959635
89	28.0	16.7	11.4	B.1.258	UKBA-1124	EPI_ISL_959636
90	18.1	16.7	1.4	B.1.1.7	UKBA-1207	EPI_ISL_959604
91	26.4	22.8	3.6	B.1.1.7	UKBA-1208	EPI_ISL_959605
92	15.5	13.3	2.3	B.1.1.7	UKBA-1209	EPI_ISL_959606
93	23.8	14.1	9.7	B.1.258	UKBA-1210	EPI_ISL_959607
94	18.4	16.9	1.5	B.1.1.7	UKBA-1211	EPI_ISL_959608
95	17.2	15.3	1.8	B.1.1.7	UKBA-1212	EPI_ISL_959609
96	22.8	21.5	1.3	B.1.1.7	UKBA-1213	EPI_ISL_959610
97	16.4	14.4	2.0	B.1.1.7	UKBA-1214	EPI_ISL_959611
98	18.9	16.9	2.1	B.1.1.7	UKBA-1215	EPI_ISL_959612
99	14.9	13.4	1.5	B.1.1.7	UKBA-1216	EPI_ISL_959613
100	16.1	14.4	1.8	B.1.1.7	UKBA-1217	EPI_ISL_959614
101	24.3	22.0	2.3	B.1.1.7	UKBA-1218	EPI_ISL_959615
102	17.6	15.3	2.3	B.1.1.7	UKBA-1219	EPI_ISL_959616
103	20.2	17.8	2.4	B.1.1.7	UKBA-1221	EPI_ISL_959617
104	15.9	14.1	1.8	B.1.1.7	UKBA-1222	EPI_ISL_959618
105	No Ct	23.9	-	B.1.258	UKBA-1223	EPI_ISL_959619
106	27.1	16.9	10.2	B.1.258	UKBA-1224	EPI_ISL_959620

\* Samples with an asterisk were re-tested due to an inconclusive result in the first test. The results depict the re-test values.

**Supplementary Table S6. Surveillance of lineage B.1.1.7 prevalence in the Slovak Republic.**

Region	B.1.1.7 ( $\Delta H69/\Delta V70 + \Delta Y144$ )	$\Delta H69/\Delta V70$ only	Other lineage of SARS- CoV-2	Inconclusive	Sample size	B.1.1.7 prevalence
<i>Retest date: 2 February 2021</i>						
<b>Banská Bystrica</b>	132	1	46	4	183	74%
<b>Bratislava</b>	306	12	73	4	395	78%
<b>Košice</b>	163	0	65	12	240	71%
<b>Nitra</b>	144	5	51	5	205	72%
<b>Prešov</b>	124	3	66	3	196	64%
<b>Trenčín</b>	131	5	25	6	167	81%
<b>Trnava</b>	357	6	57	17	437	85%
<b>Žilina</b>	69	9	54	7	139	52%
<b>Total</b>	<b>1426</b>	<b>41</b>	<b>437</b>	<b>58</b>	<b>1962</b>	<b>75%</b>
<i>Retest date: 17 February 2021</i>						
<b>Banská Bystrica</b>	242	0	156	4	402	61%
<b>Bratislava</b>	217	0	46	4	267	83%
<b>Košice</b>	235	1	114	18	368	67%
<b>Nitra</b>	101	0	45	5	151	69%
<b>Prešov</b>	145	3	45	27	220	75%
<b>Trenčín</b>	248	0	50	0	298	83%
<b>Trnava</b>	348	0	53	17	418	87%
<b>Žilina</b>	174	0	84	0	258	67%
<b>Total</b>	<b>1710</b>	<b>4</b>	<b>593</b>	<b>75</b>	<b>2382</b>	<b>74%</b>
<i>Retest date: 3 March 2021</i>						
<b>Banská Bystrica</b>	211	0	39	16	266	84%
<b>Bratislava</b>	222	1	22	11	256	91%
<b>Košice</b>	225	0	82	60	367	73%
<b>Nitra</b>	128	2	21	16	167	85%
<b>Prešov</b>	206	4	54	44	308	78%
<b>Trenčín</b>	322	7	51	32	412	85%
<b>Trnava</b>	349	6	35	19	409	89%
<b>Žilina</b>	262	1	90	4	357	74%
<b>Total</b>	<b>1925</b>	<b>21</b>	<b>394</b>	<b>202</b>	<b>2542</b>	<b>82%</b>